STOCK OPTION AGREEMENT (Director)Stock Option Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT made and entered into as of ______, 20___, by and between BioTime, Inc., a California corporation (the "Company"), and _________, a director (the "Optionee") of the Company or of a subsidiary of the Company (hereinafter included within the term "Company") within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the "Code"),
ROYALTY AGREEMENTRoyalty Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Royalty Agreement ("Agreement") is made as of October 1, 2013 (“Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation (“Asterias”), and Geron Corp., a Delaware corporation (“Geron”).
EXCLUSIVE SUBLICENSE AGREEMENT Between GERON CORPORATION and ASTERIAS BIOTHERAPEUTICS, INC.Exclusive Sublicense Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
This EXCLUSIVE SUBLICENSE AGREEMENT (the “Agreement”) is entered into as of October 1, 2013 (the “Effective Date”) by and between Geron Corporation, a Delaware corporation having a principal place of business at 149 Commonwealth Drive, Menlo Park, California 94025 (“Geron”), and Asterias Biotherapeutics, Inc., a Delaware corporation having a principal place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“Licensee”). Geron and Licensee are each referred to individually herein as a “Party,” and collectively as the “Parties.”
INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT made and entered into as of _______, 20XX, by and between BioTime, Inc., a California corporation (the "Company"), and __________, an employee (the "Employee") of the Company or of a subsidiary of the Company (hereinafter included within the term "Company") within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the "Code"),
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and GERON CORPORATION for A Method for Detecting the Differentiation of Multipotential Human Embryonic Stem Cells to Glial-Restricted Progenitor Cells that Generate Pure...Exclusive License Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
This exclusive license agreement ("Agreement") is made effective this 20th day of February, 2003, ("Effective Date"), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 ("The Regents"), and Geron Corporation, a Delaware corporation, having a principal place of business at 230 Constitution Drive, Menlo Park, California 94025 ("Licensee").
NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • Wisconsin
This Agreement is made effective as of the date of the last to sign party on page 15 (“Effective Date”), by and between the Wisconsin Alumni Research Foundation (“WARF”), a nonprofit Wisconsin corporation, and Asterias Biotherapeutics Incorporated (“Asterias”), a corporation organized and existing under the laws of Delaware, and its Affiliates who agree to sign on and be bound by the terms and obligations of this Agreement (collectively, “Licensee”). To the extent any Affiliate exercises any rights granted to Licensee hereunder, Asterias is liable to WARF for the duties and obligations of any such Affiliate, and any act or omission of an Affiliate that constitutes a breach of this Agreement shall be deemed to be a breach by Asterias.
EMPLOYMENT AGREEMENTEmployment Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
THIS EMPLOYMENT AGREEMENT (“Agreement”) is made as of August 15, 2013 by and between BioTime, Inc. (“BioTime”), a California corporation, and Lesley Stolz ("Executive").
